Abstract
Statin treatment reduces the relative risk of a coronary event by approximately 30% and consequently a high residual risk persists. Data from epidemiological, angiographic and intervention studies suggest that this residual risk could be reduced by increasing highdensity lipoprotein cholesterol (HDL-c). Approximately one out of every four patients with chronic ischemic heart disease has low HDL-c concentrations, independently of the use of statins. In this population low HDL-c levels are most frequent in women, patients with diabetes and those with criteria of metabolic syndrome. Therefore, a high percentage of patients with chronic ischemic heart disease could benefit from interventions aimed at increasing HDL-c levels.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
